Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia

European Journal of Clinical Investigation

Volumn 39, Issue 8, 2009, Pages 689-698

  Masuda, D ^a   Nakagawa Toyama, Y ^a   Nakatani, K ^a   Inagaki, M ^a   Tsubakio Yamamoto, K ^a   Sandoval, J C ^a   Ohama, T ^a   Nishida, M ^a   Ishigami, M ^b   Yamashita, S ^a  

^a OSAKA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Apolipoprotein B 48; Atherosclerosis; Ezetimibe; Postprandial hyperlipidaemia; Remnants; Triglycerides rich lipoproteins

Indexed keywords

APOLIPOPROTEIN B100; APOLIPOPROTEIN B48; CHYLOMICRON; EZETIMIBE; LIPID; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY FAT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DIET RESTRICTION; DRUG EFFECT; DRUG EFFICACY; FAT TOLERANCE TEST; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; AZETIDINES; FEMALE; HUMANS; HYPERLIPIDEMIAS; JAPAN; LIPOPROTEINS; MALE; POSTPRANDIAL PERIOD; RISK FACTORS; TRIGLYCERIDES;

EID: 68149126790     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2009.02163.x     Document Type: Article

References (24)

1. Iso H, Naito Y, Sato S, Kitamura A, Okamura T, Sankai T et al. Serum triglycerides and risk of coronary heart disease among Japanese men and women. Am J Epidemiol 2001 153 : 490 9.
2. Eberly LE, Stamler J, Neaton JD, Multiple Risk Factor Intervention Trial Research Group. Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease. Arch Intern Med 2003 163 : 1077 83.
3. Altmann SW, Davis HR Jr., Zhu LJ, Yao X, Hoos LM, Tetzloff G et al. Niemann-pick C1 like 1 protein is critical for intestinal cholesterol absorption. Science 2004 303 : 1201 4.
4. Huff MW, Pollex RL, Hegele RA. NPC1L1: evolution from pharmacological target to physiological sterol transporter. Arterioscler Thromb Vasc Biol 2006 26 : 2433 8.
5. Davis HR Jr., Hoss LM, Tetzloff G, Maguire M, Zhu LJ, Graziano MP et al. Deficiency of Niemann-Pick C1 like 1 prevents atherosclerosis in ApoE-/- mice. Arterioscler Thromb Vasc Biol 2007 27 : 841 9.
6. Davies JP, Scott C, Oishi K, Liapis A, Ioannou YA. Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia. J Biol Chem 2005 280 : 12710 20.
7. Davis HR Jr., Compton DS, Hoos L, Tetzloff G. Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice. Arterioscler Thromb Vasc Biol 2001 21 : 2032 8.
8. Garcia-Calvo M, Lisnock J, Bull HG, Hawes BE, Burnett DA, Braun MP et al. The target of ezetimibe is Niemann-Pick C1-like 1 (NPC1L1). Proc Natl Acad Sci USA 2005 102 : 8132 7.
9. Knopp RH, Dujovne CA, Le Beaut A, Lipka LJ, Suresh R, Veltri EP. Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase II clinical studies. Int J Clin Pract 2003 57 : 363 8.
10. Saito Y, Yamada N, Nakatani K, Teramoto T, Oikawa S, Yamashita S et al. Phase III clinical study of ezetimibe - double-blind comparative study with colestilan. J Clin Ther Med 2007 23 : 493 522.
11. Sakai N, Uchida Y, Ohashi K, Hibuse T, Saika Y, Tomari Y et al. Measurement of fasting serum apoB-48 levels in normolipidemic and hyperlipidemic subjects by ELISA. J Lipid Res 2003 44 : 1256 62.
12. Miyauchi K, Kayahara N, Ishigami M, Kuwata H, Mori H, Sugiuchi H et al. Development of a homogeneous assay to measure remnant lipoprotein cholesterol. Clin Chem 2007 53 : 2128 35.
13. Nakada Y, Kurosawa Y, Tohyama J, Inoue Y, Ikewaki K. Increased remnant lipoprotein in patients with coronary artery disease - evaluation utilizing a newly developed remnant assay, remnant lipoprotein cholesterol homogenous assay (RemL-C). J Atheroscler Thromb 2007 14 : 56 64.
14. Usui S, Hara Y, Hosaki S, Okazaki M. A new on-line dual enzymatic method for simultaneous quantification of cholesterol and triglycerides in lipoproteins by HPLC. J Lipid Res 2002 43 : 805 14.
15. Okazaki M, Usui S, Fukui A, Kubota I, Tomoike H. Component analysis of HPLC profiles of unique lipoprotein subclass cholesterols for detection of coronary artery disease. Clin Chem 2006 52 : 2049 53.
16. Telford DE, Sutherland BG, Edwards JY, Andrews JD, Barrett PH, Huff MW. The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatin. J Lipid Res 2007 117 : 1968 78.
17. Temel RE, Tang W, Ma Y, Rudel LL, Willingham MC, Ioannou YA et al. Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. J Clin Invest 2007 117 : 1968 78.
18. Masuda D, Hirano KI, Oku H, Sandoval JC, Kawase R, Yuasa-Kawase M et al. Chylomicron remnants are increased in the postprandial state in CD36 deficiency. J Lipid Res 2009 50 : 999 1011.
19. Labonté ED, Camarota LM, Rojas JC, Jandacek RJ, Gilham DE, Davies JP et al. Reduced absorption of saturated fatty acids and resistance to diet-induced obesity and diabetes by ezetimibe-treated and Npc1l1-/- mice. Am J Physiol Gastrointest Liver Physiol 2008 295 : G776 83.
20. González-Ortiz M, Martinez-Abundis E, Kam-Ramos AM, Hernãndez-Salazar E, Ramos-Zavala MG. Effect of ezetimibe on insulin sensitivity and lipid profile in obese and dyslipidaemic patients. Cardiovasc Drugs Ther 2006 20 : 143 6.
21. van Heek M, Austin TM, Farley C, Cook JA, Tetzloff GG, Davis HR. Ezetimibe, a potent cholesterol absorption inhibitor, normalizes combined dyslipidemia in obese hyperinsulinemic hamsters. Diabetes 2001 50 : 1330 5.
22. Deushi M, Nomura M, Kawakami A, Haraguchi M, Ito M, Okazaki M et al. Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. FEBS Lett 2007 581 : 5664 70.
23. Sager PT, Capece R, Lipka L, Strony J, Yang B, Suresh R et al. Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients. Atherosclerosis 2005 179 : 361 7.
24. Bulut D, Hanefeld C, Bulut-Streich N, Graf C, Mügge A, Spiecker M. Endothelial function in the forearm circulation of patients with the metabolic syndrome - effect of different lipid-lowering regimens. Cardiology 2005 104 : 176 80.